Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Department of Surgical Nursing, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Front Cell Infect Microbiol. 2022 Jul 12;12:962782. doi: 10.3389/fcimb.2022.962782. eCollection 2022.
Intestinal ischemia/reperfusion (II/R) is a common acute and critical condition in clinical practice with a high mortality rate. However, there is still a lack of effective prevention and treatment measures for II/R injury. The role of the gut microbiota in II/R has attracted widespread attention. Recent evidence has demonstrated that the gut microbiota plays a pivotal role in the occurrence, development, and prognosis of II/R. Therefore, maintaining the homeostasis of gut microbiota and its metabolites may be a potential strategy for the treatment of II/R. This review focuses on the importance of crosstalk between the gastrointestinal ecosystem and II/R to highlight II/R-induced gut microbiota signatures and potential applications of microbial-based therapies in II/R. This will also provide potentially effective biomarkers for the prediction, diagnosis and treatment of II/R.
肠缺血/再灌注（II/R）是临床实践中常见的急性危重症，死亡率高。然而，目前对于 II/R 损伤仍然缺乏有效的预防和治疗措施。肠道微生物群在 II/R 中的作用引起了广泛关注。最近的证据表明，肠道微生物群在 II/R 的发生、发展和预后中起着关键作用。因此，维持肠道微生物群及其代谢物的平衡可能是治疗 II/R 的一种潜在策略。本综述重点关注胃肠道生态系统与 II/R 之间的相互作用的重要性，以突出 II/R 诱导的肠道微生物群特征和基于微生物的疗法在 II/R 中的潜在应用。这也将为 II/R 的预测、诊断和治疗提供潜在的有效生物标志物。
